ClinicalTrials.gg
TerminatedNCT03672643Updated Nov 8, 2024Results posted

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

A Phase 4 interventional study of Crizotinib in ALK or ROS1-positive NSCLC, sponsored by Pfizer. Terminated at 14 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Why this study was terminated
The trial is terminated based on business decision, not due to safety concerns or regulatory requirements.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is to allow access to crizotinib who were treated in previous Pfizer-sponsored studies in China.

Read the detailed description

This study is a phase 4 study, to continually access Xalkori to Chinese patients who were recruited in previous studies of Crizotinib in China, and only collect the safety data.

02

Conditions studied

  • ALK or ROS1-positive NSCLC

Keywords

  • NSCLC
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who were enrolled and treated in Studies A8081005, A8081007, A8081014, A8081029, or A8081063 and are still receiving crizotinib treatment at the time of enrollment into this study. OR Patients randomized to the chemotherapy arm in Studies A8081014 or A8081029 who have experienced investigator assessed disease progression and have not yet crossed over to receive crizotinib treatment.
  2. No ongoing Grade 3 or intolerable Grade 2 adverse events considered to be related to crizotinib treatment
  3. (ECOG) performance status 0-3
  4. Adequate organ function as defined by the following criteria

Exclusion criteria

Exclusion Criteria:

  1. Use of any anticancer drug subsequent to crizotinib prior to study entry
  2. Use of drugs or foods that are known potent Cytochrome P450 (CYP)3A4 inhibitors
  3. Use of drugs that are known potent inducers
  4. Concurrent use of drugs that are CYP3A4 substrates with narrow therapeutic indices, associated with life threatening arrhythmias
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Other
    single arm

    Crizotinib

    Drug: Crizotinib

Interventions

  • receive crizotinib orally

    Also known as: Xalkori

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grade 3 or 4 Adverse Events (AEs), Grade 5 AEs, AEs Lead to Treatment Discontinuation, Serious AEs (SAEs)- All Causality: Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03

    An AE was any untoward medical occurrence in a clinical study participant associated with the use of study intervention, whether or not considered related to the study intervention. According to NCI CTCAE version 4.03: Grade 3 indicates severe AE, Grade 4 indicates life-threatening consequences and urgent intervention indicated and Grade 5 indicates death related to AE. Participants who discontinued treatment due to AEs were captured under AEs leading to treatment discontinuation. SAE was any untoward medical occurrence at any dose that resulted in death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect or that was considered as an important medical event.

    Time frame: From first dose of study treatment up to 28 days after last dose (maximum follow up approximately up to 52.3 months; maximum exposure to treatment was 51.3 months)

  2. Number of Participants With Grade 3 or 4 AEs, Grade 5 AEs, AEs Leading to Treatment Discontinuation and SAEs- Treatment Related: Assessed by NCI CTCAE v4.03

    An AE was any untoward medical occurrence in a clinical study participant associated with use of study intervention, whether or not considered related to study intervention. AEs that were related to treatment were evaluated in this outcome measure. Treatment relatedness was judged by investigator. According to NCI CTCAE version 4.03: Grade 3= severe AE, Grade 4= life-threatening consequences and urgent intervention indicated, Grade 5= death related to AE. Participants who discontinued treatment due to treatment related AEs were captured under AEs leading to treatment discontinuation. SAE was any untoward medical occurrence at any dose that resulted in death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect or that was considered as an important medical event.

    Time frame: From first dose of study treatment up to 28 days after last dose (maximum follow up approximately up to 52.3 months; maximum exposure to treatment was 51.3 months)

07

Results

Posted Nov 8, 2024

Participant flow

Participant flow — Overall Study
MilestoneCrizotinib
Started41
Completed0
Not completed41
Withdrew: Adverse event3
Withdrew: Death2
Withdrew: Withdrawal by subject1
Withdrew: Progressive disease11
Withdrew: Global deterioration of health status1
Withdrew: Refused further treatment7
Withdrew: Rolled over to a continuous study for crizotinib treatment16

Outcome measures

PrimaryNumber of Participants With Grade 3 or 4 Adverse Events (AEs), Grade 5 AEs, AEs Lead to Treatment Discontinuation, Serious AEs (SAEs)- All Causality: Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03

An AE was any untoward medical occurrence in a clinical study participant associated with the use of study intervention, whether or not considered related to the study intervention. According to NCI CTCAE version 4.03: Grade 3 indicates severe AE, Grade 4 indicates life-threatening consequences and urgent intervention indicated and Grade 5 indicates death related to AE. Participants who discontinued treatment due to AEs were captured under AEs leading to treatment discontinuation. SAE was any untoward medical occurrence at any dose that resulted in death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect or that was considered as an important medical event.

Time frame:
From first dose of study treatment up to 28 days after last dose (maximum follow up approximately up to 52.3 months; maximum exposure to treatment was 51.3 months)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or 4 Adverse Events (AEs), Grade 5 AEs, AEs Lead to Treatment Discontinuation, Serious AEs (SAEs)- All Causality: Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03
ParticipantsCrizotinib
Grade 3 or 4 AEs19
Grade 5 AEs2
AEs Leading to Treatment Discontinuation4
SAEs13
PrimaryNumber of Participants With Grade 3 or 4 AEs, Grade 5 AEs, AEs Leading to Treatment Discontinuation and SAEs- Treatment Related: Assessed by NCI CTCAE v4.03

An AE was any untoward medical occurrence in a clinical study participant associated with use of study intervention, whether or not considered related to study intervention. AEs that were related to treatment were evaluated in this outcome measure. Treatment relatedness was judged by investigator. According to NCI CTCAE version 4.03: Grade 3= severe AE, Grade 4= life-threatening consequences and urgent intervention indicated, Grade 5= death related to AE. Participants who discontinued treatment due to treatment related AEs were captured under AEs leading to treatment discontinuation. SAE was any untoward medical occurrence at any dose that resulted in death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect or that was considered as an important medical event.

Time frame:
From first dose of study treatment up to 28 days after last dose (maximum follow up approximately up to 52.3 months; maximum exposure to treatment was 51.3 months)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or 4 AEs, Grade 5 AEs, AEs Leading to Treatment Discontinuation and SAEs- Treatment Related: Assessed by NCI CTCAE v4.03
ParticipantsCrizotinib
Treatment Related Grade 3 or 4 AEs11
Treatment Related Grade 5 AEs0
Treatment Related AEs Leading to Treatment Discontinuation1
Treatment Related SAEs4

Adverse events

Collected over From first dose of study treatment up to 28 days after last dose (maximum follow up approximately up to 52.3 months; maximum exposure to treatment was 51.3 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crizotinib3/41 (7.3%)13/41 (31.7%)8/41 (19.5%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventCrizotinib
Disease progressionGeneral disorders2/41
Crohn's diseaseGastrointestinal disorders1/41
Gastrointestinal haemorrhageGastrointestinal disorders1/41
Impaired gastric emptyingGastrointestinal disorders1/41
Obstruction gastricGastrointestinal disorders1/41
Pancreatitis acuteGastrointestinal disorders1/41
Anal abscessInfections and infestations1/41
Herpes zosterInfections and infestations1/41
PneumoniaInfections and infestations1/41
Postoperative wound infectionInfections and infestations1/41
Most frequent other events
Most frequent other events
EventCrizotinib
Neutrophil count decreasedInvestigations8/41
White blood cell count decreasedInvestigations3/41

Baseline characteristics

Full analysis set (FAS) included all participants who had been enrolled in the study, regardless of whether treatment was received.

Age, Continuous
Age, Continuous(Years)Crizotinib
Mean58.0 ± 12.14
Sex: Female, Male
Sex: Female, Male(Participants)Crizotinib
Female24
Male17
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Crizotinib
Race: Asian41
Ethnicity: Not Hispanic or Latino41
08

Study locations

14 sites
  • Fujian Province Oncology Hospital
    Fuzhou, Fujian 350014, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Liwan District,Guangzhou, Guangdong 510145, China
  • Eastern Theater General Hospital ,QinHuai District Medical Area
    Nanjing, Jiangsu 210002, China
  • Jilin Province Cancer Hospital
    Changchun, Jilin 130000, China
  • Jilin Provincial Cancer Hospital
    Changchun, Jilin 130012, China
  • Shanghai Chest Hospital
    Shanghai, Shanghai 200030, China
  • Sichuan Province Cancer Hospital/Department of Pulmonary Tumor
    Chengdu, Sichuan 610041, China
  • Sichuan Province Cancer Hospital
    Chengdu, Sichuan 610041, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Department of Respiratory, The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • Beijing Cancer Hospital, Internal Department
    Beijing, 100142, China
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Sep 2023, 56 months.

Results were first posted in Nov 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2018
First posted
Sep 14, 2018
StartActual
Jan 28, 2019
Primary completionActual
Sep 28, 2023
CompletionActual
Sep 28, 2023
Results first posted
Nov 8, 2024
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03672643
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 14, 2018
Start date
Jan 28, 2019
Primary completion
Sep 28, 2023
Completion
Sep 28, 2023
Results posted
Nov 8, 2024
Last update
Nov 8, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion